Table 3. OS and prognostic factors in 94 infants with stage 4s neuroblastoma.

Parameter		N	3-year OS (%) (±2 s.e.)	P (log-rank)
Total population		94	88 (±7.6)
Age at diagnosis	⩽60 days	51	83 (±12.2)	0.18
	>60 days	43	93 (±8)
	⩽90 days	62	82 (±11.4)
	>90 days	32	96 (±6)	<0.06
	⩽120 days	73	84 (±9.8)
	>120 days	21	100	0.06
Primary tumour	Abdominal	82	89 (±7.8)
	Extra-abdominal	7	71 (±31.2)	0.12
Metastasis	No liver metastasis	7	100
	Liver metastasis	87	87 (±8.2)	0.33
	No cutaneous metastasis	78	88 (±8.2)
	Cutaneous metastasis	16	87 (±16.8)	0.87
	No bone marrow metastasis	59	86 (±10)
	Bone marrow metastasis	27	88 (±13)	0.75
Medical treatment	Supportive	37	100
	chemotherapy and/or radiotherapy	57	80 (±11.8)	0.0049
Surgery	Resection of primary	69	94 (±6.6)
	No resection of primary	25	71 (±18)	0.0018
Urinary dopamine	⩽2500 nmol mmol−1 creatinine	59	93 (±7.4)
	>2500 nmol mmol−1 creatinine	22	78 (±18)	<0.05
Serum LDH	⩽600 IU l−1	12	100
	>600 IU l−1	22	85 (±16.4)	0.23
Serum ferritin	⩽280 ng ml−1	30	93 (±9)
	>280 ng ml−1	9	66 (±29)	0.03
Serum NSE	⩽100 nmol ml−1	32	100
	>100 nmol ml−1	11	54 (±27.8)	<0.0005
N-myc status	No NMA	59	93 (±6.8)
	NMA	4	0	<0.0005
1p status	No 1p deletion	17	100
	1p deletion	6	44 (±38.2)	0.0016